Where I see patients (3)
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
British journal of haematology
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause.
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed...
MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity (DLT), will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4...
Soothing the soul